Maxivision Super Speciality Eye Hospitals has launched SMILE Pro (VISUMAX 800), a laser vision correction system, at its Somajiguda facility in Hyderabad. Actor Nagarjuna Akkineni launched the technology, which is designed to treat myopia and astigmatism in eligible patients. The announcement came on 2 November 2026.

The procedure is built around speed. According to the hospital’s press release, the system requires less than 10 seconds of laser exposure. The company describes it as next-generation laser surgery that is minimally invasive, performed through a small incision.

Faster Treatment, Finer Precision

The press release frames the system around two goals: faster treatment and surgical precision. Those are the two claims the hospital chose to lead with, and they sit at the center of how Maxivision is positioning the platform for eligible patients.

Myopia, often called short-sightedness, makes distant objects look blurred while nearby ones stay clear. Astigmatism affects how light focuses inside the eye, distorting vision at different distances. Both are common vision problems, and both are the targets of the new system.

What the Procedure Involves

SMILE stands for small incision lenticule extraction. It is a form of laser eye surgery that reshapes the cornea by removing a thin, lens-shaped piece of corneal tissue through a small opening, rather than lifting a flap as in some older laser methods. The press release describes SMILE Pro in similar terms, as minimally invasive correction through a small incision. The release does not go into the surgical steps in more detail.

Because the correction works by reshaping the cornea, it is considered permanent in a way that eyeglasses and contact lenses are not. Once the tissue is reshaped, the change does not wear off when the device is removed. Eyes can still change with age, so follow-up checks remain part of care after surgery.

Eligibility for laser refractive procedures typically depends on a full eye evaluation, including corneal thickness and whether the prescription has stayed stable. These are standard screening steps across the field. The Maxivision release says only that the system is meant for eligible patients and does not list its own criteria.

A First Claim for Telangana

The launch carries a regional angle. Dr. Varun Malhotra, Chief Clinical Officer at Maxivision Super Speciality Eye Hospitals, made a specific claim about the company’s position in the state.

“We are proud to be the first corporate eye care chain in Telangana to introduce this advanced laser vision correction technology”

Because the facility sits in Hyderabad, the state capital, the rollout gives patients in the city a named location where the technology is now available. The claim is about the corporate eye care sector specifically, which the release presents as the basis for the first-in-state label.

The Leadership Angle

Dr. Kasu Prasad Reddy, Founder of Maxivision Super Speciality Eye Hospitals, placed the launch within a broader strategy. He said the introduction of SMILE Pro reflects the company’s continued commitment to adopting advanced technologies that support precision-driven treatments and enhance the overall patient experience.

That framing puts the emphasis on the experience around the procedure, not only on the laser itself. The system was launched in the presence of senior leadership from Maxivision, a sign that the company is treating the rollout as a major institutional step rather than a routine equipment addition.

What the Announcement Leaves Out

The press release does not disclose pricing, the number of procedures performed on the platform, or expected recovery timelines. It also does not say how many patients are currently eligible or what outcome data supports the speed and precision claims. Those details matter for anyone weighing permanent vision correction, and the announcement does not address them.

Whether SMILE Pro becomes a common choice for vision correction in Hyderabad will depend on those answers and on patient results over time. For now, the verified facts are narrow: one named facility, one named technology, and a launch fronted by a public figure, with eligibility left to a clinical examination.